Bioage Labs Inc (BIOA)

$18.06 +1.01 (5.92%)
Market Cap 756.68M
Revenue (ttm) 9.00M
Net Income (ttm) -80.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -895.67%
Debt to Equity Ratio 0.01
Volume 348,767
Avg Vol 541,318
Day's Range N/A - N/A
Shares Out 44.38M
Stochastic %K 19%
Beta 1.80
Analysts Strong Sell
Price Target $53.33

Company Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 806 1445
Address:
5885 Hollis Street, Suite 370, Emeryville, United States
skyrockets_Inc
skyrockets_Inc Apr. 21 at 5:08 PM
$VTGN Likely in coming weeks. They announced data as '1H 2026' instead of Q2. $BIOA announced the same thing '1H 2026' and just released their data today. I think we are due within weeks, possibly by end of April.
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 2:44 PM
$BIOA Pros: - best-in-class reduction of inflammation - oral - brain-penetrant (allows ophthalmolgy and CNS indications) - huge TAMs - last funding at $19.5 - runway through 2029 - NVO and LLY partnerships Cons - too early stage (unless it gets acquired...) with many unknowns
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 1:06 PM
$BIOA As clarified in the call headache was associated with lumbar punctures consucted in treatment arms for pk/pd studies
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:20 PM
$BIOA Targeting/potential in many large TAMs: - CVD disease - obesity - DME, GA Room for >1 players too
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:13 PM
$BIOA best hsCRP reduction + oral + brain-penetrant
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 21 at 11:43 AM
$BIOA https://ir.bioagelabs.com/news-releases/news-release-details/bioage-reports-positive-phase-1-data-bge-102-novel-oral-nlrp3
0 · Reply
S2K_TP
S2K_TP Apr. 18 at 5:41 PM
$BIOA still watching this 20 break at some point
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 1:31 AM
$BIOA RSI: 43.08, MACD: -0.8938 Vol: 1.92, MA20: 18.86, MA50: 19.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 6:43 PM
$BIOA Share Price: $16.27 Contract Selected: Dec 18, 2026 $22.5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.36 – $1.67 Potential Upside: 52% ROI Time to Expiration: 265 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
notreload_ai
notreload_ai Mar. 27 at 12:38 PM
Needham started coverage of $BIOA with a Buy rating and $50 price target. Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients. https://notreload.xyz/needham-initiates-buy-rating-on-bioage-labs/
0 · Reply
Latest News on BIOA
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

Apr 21, 2026, 11:07 AM EDT - 6 days ago

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

BioAge Labs Transcript: Study result

Apr 21, 2026, 8:00 AM EDT - 6 days ago

BioAge Labs Transcript: Study result

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

Apr 21, 2026, 7:00 AM EDT - 6 days ago

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 3:00 PM EDT - 11 days ago

BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 4:30 PM EDT - 14 days ago

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:40 AM EST - 2 months ago

BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

Jan 21, 2026, 10:30 PM EST - 3 months ago

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Announces Proposed Public Offering

Jan 20, 2026, 4:01 PM EST - 3 months ago

BioAge Announces Proposed Public Offering

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

Jan 20, 2026, 9:00 AM EST - 3 months ago

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

Jan 12, 2026, 9:00 AM EST - 3 months ago

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 1:30 PM EST - 5 months ago

BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Dec 4, 2025, 9:00 AM EST - 5 months ago

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:30 PM EST - 5 months ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

BioAge Labs Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 7:30 AM EST - 5 months ago

BioAge Labs Transcript: Jefferies London Healthcare Conference 2025

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Nov 7, 2025, 9:00 AM EST - 6 months ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Sep 15, 2025, 9:30 AM EDT - 8 months ago

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:00 AM EDT - 8 months ago

BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

BioAge Labs Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 3:15 PM EDT - 8 months ago

BioAge Labs Transcript: Citi's Biopharma Back to School Conference

BioAge Labs to Present at Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 8 months ago

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Aug 15, 2025, 9:00 AM EDT - 9 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 4:30 PM EDT - 9 months ago

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Jun 21, 2025, 6:00 PM EDT - 11 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

Jun 17, 2025, 9:00 AM EDT - 11 months ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 3:20 PM EDT - 11 months ago

BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

Mar 10, 2025, 9:30 PM EDT - 1 year ago

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 10, 2025, 6:33 PM EDT - 1 year ago

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

Mar 7, 2025, 4:11 PM EST - 1 year ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO - Hagens Berman

Mar 6, 2025, 1:30 PM EST - 1 year ago

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO - Hagens Berman

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 5, 2025, 3:45 PM EST - 1 year ago

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman

Mar 3, 2025, 3:19 PM EST - 1 year ago

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

Mar 2, 2025, 7:23 AM EST - 1 year ago

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman

Mar 1, 2025, 6:00 PM EST - 1 year ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Feb 28, 2025, 3:30 PM EST - 1 year ago

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 27, 2025, 9:24 AM EST - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

Feb 27, 2025, 5:45 AM EST - 1 year ago

Investors in BioAge Labs, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Feb 23, 2025, 9:24 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

BioAge Labs Transcript: Citi's 2024 Global Healthcare Conference

Dec 4, 2024, 3:15 PM EST - 1 year ago

BioAge Labs Transcript: Citi's 2024 Global Healthcare Conference

BioAge Labs Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 1:30 PM EST - 1 year ago

BioAge Labs Transcript: Piper Sandler 36th Annual Healthcare Conference

BioAge Labs Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 8:00 AM EST - 1 year ago

BioAge Labs Transcript: Jefferies London Healthcare Conference 2024

skyrockets_Inc
skyrockets_Inc Apr. 21 at 5:08 PM
$VTGN Likely in coming weeks. They announced data as '1H 2026' instead of Q2. $BIOA announced the same thing '1H 2026' and just released their data today. I think we are due within weeks, possibly by end of April.
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 2:44 PM
$BIOA Pros: - best-in-class reduction of inflammation - oral - brain-penetrant (allows ophthalmolgy and CNS indications) - huge TAMs - last funding at $19.5 - runway through 2029 - NVO and LLY partnerships Cons - too early stage (unless it gets acquired...) with many unknowns
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 1:06 PM
$BIOA As clarified in the call headache was associated with lumbar punctures consucted in treatment arms for pk/pd studies
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:20 PM
$BIOA Targeting/potential in many large TAMs: - CVD disease - obesity - DME, GA Room for >1 players too
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:13 PM
$BIOA best hsCRP reduction + oral + brain-penetrant
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 21 at 11:43 AM
$BIOA https://ir.bioagelabs.com/news-releases/news-release-details/bioage-reports-positive-phase-1-data-bge-102-novel-oral-nlrp3
0 · Reply
S2K_TP
S2K_TP Apr. 18 at 5:41 PM
$BIOA still watching this 20 break at some point
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 1:31 AM
$BIOA RSI: 43.08, MACD: -0.8938 Vol: 1.92, MA20: 18.86, MA50: 19.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 6:43 PM
$BIOA Share Price: $16.27 Contract Selected: Dec 18, 2026 $22.5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.36 – $1.67 Potential Upside: 52% ROI Time to Expiration: 265 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
notreload_ai
notreload_ai Mar. 27 at 12:38 PM
Needham started coverage of $BIOA with a Buy rating and $50 price target. Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients. https://notreload.xyz/needham-initiates-buy-rating-on-bioage-labs/
0 · Reply
Steppinstone
Steppinstone Mar. 26 at 2:01 AM
$BIOA Full set of Phase 1 data including last obese cohort should be reported sometime within 90 days. Phase 2a trial is guided to initiate within 90 days in CV along with Phase 1/2 trial in DME and then GA. Remember Lilly acquired Ventryx a few months ago for its NLRP3 inhibitor. BIOA has the best one in class.
0 · Reply
NoKaOi
NoKaOi Mar. 23 at 2:49 PM
$BIOA might stay to tip toe back in. Seeing where this falls to.
0 · Reply
Bazzzigar
Bazzzigar Mar. 14 at 2:56 PM
$BIOA join with HIMS
0 · Reply
erevnon
erevnon Mar. 10 at 2:56 PM
Citigroup maintains Bioage Labs $BIOA at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
NoKaOi
NoKaOi Mar. 2 at 6:33 PM
$IBRX Sold 1000 of my $BIOA going to sit at $10.70
0 · Reply
NoKaOi
NoKaOi Mar. 2 at 10:59 AM
$BIOA in for 1000 shares at $20.25. Quietly watching.
0 · Reply
erevnon
erevnon Feb. 25 at 11:25 AM
Oppenheimer initiates coverage on Bioage Labs $BIOA at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:01 AM
$BIOA Current Stock Price: $19.56 Contracts to trade: $20.0 BIOA Feb 20 2026 Call Entry: $2.79 Exit: $4.30 ROI: 54% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
notreload_ai
notreload_ai Feb. 18 at 1:40 PM
Wall Street analysts are bullish on $ZBIO and $BIOA with strong upgrades, highlighting near-term FDA potential and promising drug data for big growth in 2026. https://notreload.xyz/zenas-biopharma-bioage-labs-hot-biotech-upgrades-to-watch/
0 · Reply
anachartanalyst
anachartanalyst Feb. 18 at 1:02 PM
$BIOA https://anachart.com/wp-content/uploads/ana_temp/1771419687_soc-img.jpg
0 · Reply
erevnon
erevnon Feb. 18 at 12:22 PM
Jefferies upgrades Bioage Labs $BIOA from Hold to Buy and raises the price target from $9 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
TraderHispania
TraderHispania Feb. 18 at 12:05 PM
$BIOA JEFFERIES RAISES TO BUY FROM HOLD; RAISES TARGET PRICE TO $62 FROM $9 ...
0 · Reply